Investigating how CD40 immunotherapy affects heart immune responses and myocardial disease.
Official title: CD40 Immunotherapy Effect on the Cardiac Immune Landscape and Response to Myocardial Disease
Funded at Washington University · NIH-10988312 · Data updated 2026-11-12
This study is looking at how a treatment called CD40 immunotherapy affects the heart's immune system, especially for people with heart issues who are also receiving cancer treatments, to see if it might cause any heart problems.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $162,935 |
| NIH project number | 5K08HL163518-02 |
| Project ID | NIH-10988312 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients receiving immunotherapy who may be at risk for cardiac complications.
✕Less likely to help
Patients not undergoing immunotherapy or those without existing heart conditions may not benefit from this research.
What this research studies
This research explores the effects of CD40 immunotherapy on the immune landscape of the heart, particularly in relation to myocardial disease. It aims to understand how CD40 signaling can activate immune responses that may lead to cardiac injury, especially in patients undergoing cancer treatment with immune checkpoint inhibitors. By examining the interactions between antigen-presenting cells and T-cells, the study seeks to identify mechanisms that could contribute to adverse cardiac events. Patients may be monitored for changes in heart health and immune responses during the treatment process.
Why it matters
Potential benefit: If successful, this research could lead to safer immunotherapy options for cancer patients, minimizing the risk of heart-related side effects.
How similar studies have gone: While immunotherapy has shown success in treating cancer, the specific effects of CD40 agonists on cardiac health are still being explored, making this research a novel investigation.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Jimenez, Jesus — Washington University
- Study coordinator: Jimenez, Jesus
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.